The Barcelona-based firm, which has a protein splicing platform that aims to address the major limitation of delivering large genes using AAV vectors, has sealed the largest series A fundraising by a Spanish biotech.
Gene therapy is hardly flavor of the month for investors at the moment but that has not stopped SpliceBio from signing off the largest ever series A financing in Spain for a biotech company.
SpliceBio has completed an oversubscribed €50m finance round co-led by UCB Ventures and existing shareholder Ysios Capital. The latter has...
Create an account to read this article
Already a subscriber?
Private Company Edition: Braveheart Bio licensed its selective cardiac myosin inhibitor from Hengrui. Also, Arena BioWorks shuts down after raising $500m in 2024, GHO Capital closed a €2.5bn ($2.9bn) private equity fund and new cash brings Tubulis’s series C to €344m ($401m).
Lower interest rates, M&A activity and a string of positive clinical trial readouts have boosted biopharma investor sentiment in a recovery that appears sustainable, according to William Blair healthcare capital markets managing director Kevin Eisele.
While other gene therapies disease areas have fallen out of favor, eye disease candidates seem to be attracting more funding. Italy-based AAVantgarde is the latest to achieve a mega-round.
Public Company Edition: MapLight grossed $288.4m plus $8.1m from a private placement to fund neuropsychiatry clinical trials. Also, Evommune set a price range for its pending IPO of up to $183.3m, Sanofi priced a $3bn bond issue and Arcus raised $250m in a follow-on offering.
Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call
South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.
Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.
